Oct
20
Tue
Frontiers in Oncology: From Intern to Chief: A Tale of Partnerships and Persistence with a Vision for the Future @ Online only
Oct 20 @ 8:00 am – 9:00 am
Frontiers in Oncology: From Intern to Chief: A Tale of Partnerships and Persistence with a Vision for the Future @ Online only

From Intern to Chief: A Tale of Partnerships and Persistence with a Vision for the Future

Dr. Heather Wakelee is a Professor of Medicine in the Division of Oncology at Stanford University and is the faculty director of the Stanford Cancer Clinical Trials Office. Dr. Wakelee has authored or co-authored over 200 medical articles on lung cancer and other thoracic malignancies and is involved in dozens of clinical trials related to lung cancer therapy and diagnostics. Her research focuses on many specific lung cancer subtypes defined by specific mutations in EGFR, ALK, ROS1, RET, BRAF and others. She is also involved in trials of adjuvant therapy, immunotherapy and anti-angiogenesis agents in addition to collaborations with colleagues focused in biomarkers and others focused in population science research.

Dr. Wakelee is active in multiple national and international lung cancer research organizations including serving as a member of the Board of Directors of the International Association for the Study of Lung Cancer (IASLC), co-chair of the thoracic committee and Stanford Principal Investigator for the Eastern Cooperative Oncology Group (ECOG-ACRIN), and as a Fellow of the American Society of Clinical Oncology (FASCO).

Join us on Zoom: http://bit.ly/FIOWakelee Password: 383676

Jun
9
Fri
SCCR Virtual Science Series: The Stanford experience: Pioneering the clinical treatment of mixed hematopoietic chimerism to induce transplantation tolerance @ Zoom Meeting Link
Jun 9 @ 9:00 am – 11:00 am
SCCR Virtual Science Series: The Stanford experience:  Pioneering the clinical treatment of mixed hematopoietic chimerism to induce transplantation tolerance @ Zoom Meeting Link


Speakers: Dr. Everett Meyer, MD, PhD, and Dr. Stephan Busque, MD

Click HERE to Register!

Zoom Class Link

The mission of the Stanford Center for Clinical Research (SCCR) includes offering educational resources, training, and support for investigators and research staff.  We have invited the Associate Professor of Medicine, BMT and Cell Therapy, Dr. Everett Meyer, MD, PhD, and the Professor of Surgery and Abdominal Transplantation, Dr. Stephan Busque, MD, to provide you with the Stanford Experience on the Cell Immune Therapy Tolerance, and discuss a patient experience as CIT trial participant. The speakers will review the genesis and development of the “Strober Protocol” where kidney transplant patients also get a minimally intensive allogeneic hematopoietic transplant from their patient. They will review how clinical trial conduct has been implemented and developed.

At the conclusion of this class, you will be able to:

  • Explain the biology and science of how mixed hematopoietic chimerism induces immune tolerance.
  • Review two decades of clinical trial results testing kidney and hematopoietic stem cell transplantation at Stanford.
  • Understand clinical trial conduct and successes and challenges of these trial.
  • Discuss patient experience being a trial participant.

Attendance is open to all research staff.

About the Presenters:

Dr. Everett Meyer, MD, PhD, MS, is an Associate Professor in the division of Blood and Marrow Transplantation and Cellular Therapy, with courtesy appointments in Surgery and Pediatrics. He has a focus on the pre-clinical and clinical study of immune tolerance. He serves as director of the Cellular Immune Tolerance program supported by DOM and Surgery and which receives critical clinical trial support from SCCR. His scientific focus is the study of hematopoietic chimerism and T regulatory cell therapy.
Dr. Stephan Busque, MD, is a Professor in the division of Abdominal Transplantation Surgery. He serves as Director Adult Kidney and Pancreas Transplant Program and Surgical Director of the Cellular Immune Tolerance Program and is widely regarded as a leading expert in the clinical implementation of immune tolerance in kidney transplantation. His research interest is focused on the improvement of clinical immunosuppression. He is involved in the evaluation of new immunosuppressive drugs, potentially more efficacious or less toxic, with the ultimate goal to achieve tolerance.

BRN OPTIONAL 

Spectrum is an approved provider by the California Board of Registered Nursing, Provider Number CEP15435 for 2 contact hour(s).
To receive your certificate with BRN credit, you are required to complete an evaluation at the conclusion of this class.
BRN Cancellation Policy: If you wish to cancel your registration, please contact the course coordinators, Susan Saba, ssaba@stanford.edu.